<?xml version="1.0" encoding="UTF-8"?>
<p id="par0075">For example, novel anti-ZIKV activities of enoxacin, amodiaquine and niclosamide were discovered recently using human neural progenitor cells, human pluripotent stem cell-derived cortical neural progenitor cells, and human induced neural stem cells, respectively (
 <xref rid="bib0060" ref-type="bibr">Cairns et al., 2018</xref>, 
 <xref rid="bib0535" ref-type="bibr">Xu et al., 2019</xref>, 
 <xref rid="bib0585" ref-type="bibr">Zhou et al., 2017</xref>). Enoxacin is an oral broad-spectrum fluoroquinolone antibiotic, which also possesses anti-HCV and anti-HIV-1 activities in immortalized cell cultures (
 <xref rid="bib0220" ref-type="bibr">Kashiwase et al., 1999</xref>, 
 <xref rid="bib0560" ref-type="bibr">Young et al., 2010</xref>). Amodiaquine is an anti-malaria drug, which also possesses antiviral activities against DENV, HCV, RRV, SINV, WNV, EFV, EBOV, LASV, RABV, VZV, and HSV-1 in immortalized cell cultures (
 <xref rid="bib0045" ref-type="bibr">Boonyasuppayakorn et al., 2014</xref>, 
 <xref rid="bib0180" ref-type="bibr">Hulseberg et al., 2019</xref>, 
 <xref rid="bib0300" ref-type="bibr">Mazzon et al., 2019</xref>). Niclosamide is an orally bioavailable anthelmintic drug which inhibits the broadest range of viruses in vitro and, in some cases, in vivo (
 <xref rid="bib0060" ref-type="bibr">Cairns et al., 2018</xref>, 
 <xref rid="bib0125" ref-type="bibr">Fang et al., 2013</xref>, 
 <xref rid="bib0175" ref-type="bibr">Huang et al., 2017</xref>, 
 <xref rid="bib0180" ref-type="bibr">Hulseberg et al., 2019</xref>, 
 <xref rid="bib0210" ref-type="bibr">Jurgeit et al., 2012</xref>, 
 <xref rid="bib0215" ref-type="bibr">Kao et al., 2018</xref>, 
 <xref rid="bib0300" ref-type="bibr">Mazzon et al., 2019</xref>, 
 <xref rid="bib0460" ref-type="bibr">Stachulski et al., 2011</xref>, 
 <xref rid="bib0495" ref-type="bibr">Wang et al., 2016</xref>, 
 <xref rid="bib0515" ref-type="bibr">Wu et al., 2004</xref>). These safe-in-man BSAAs represent promising drug candidates.
</p>
